We provide a clinically useful, reliable, comprehensive, up-to-date, evidence-based drug-drug interaction resource, freely available to healthcare workers, patients and researchers.
Currently 170 million people worldwide are infected with the hepatitis C virus (HCV) and >300 million with hepatitis B (HBV). Although interferon-free combination direct acting antivirals (DAAs) regimens have improved tolerability and efficacy for HCV-infected patients, drug-drug interactions (DDIs) have the potential to cause harm due to liver dysfunction, multiple comorbidities and comedications. This web site was established in 2010 by members of the Department of Pharmacology at the University of Liverpool to offer a resource for healthcare providers, researchers and patients to be able to understand and manage drug-drug interactions.
We strongly believe that drug information should be offered free of charge, be independent, and be evidence-based and transparent. We have an international Editorial Board with strong patient and user involvement. We are convinced that quality of care is vitally important, particularly in resource-limited countries where health systems may be weak or fragmented, patient monitoring sparse, and where patient harms from DDIs may pass unnoticed. We actively promote the use of our Apps to healthcare providers and patients to enable rapid screening of DDIs.
Information presented relates only to known or suspected effects of interacting medications, and is based on relevant data in the public domain. No clinical advice is given or implied, clinicians must exercise their own judgement in relation to the risks and benefits of combining drugs, which depend on factors beyond pharmacokinetic interactions between two drugs. The University of Liverpool shall not be held responsible for the application or use of any information it gives and the user shall hold the University of Liverpool harmless against any consequences arising from the same.